

SLC6A4 RABBIT PAB

货号: S220361

产品全名: SLC6A4 兔多抗

基因符号: HTT; 5HTT; OCDI; SERT; 5-HTT; SERT1; hSERT; 5-HTTLPR

UNIPROT ID: P31645 (Gene Accession - NP_001036)

背景: This gene encodes an integral membrane protein that transports the neurotransmitter serotonin from synaptic spaces into presynaptic neurons. The encoded protein terminates the action of serotonin and recycles it in a sodium-dependent manner. This protein is a target of psychomotor stimulants, such as amphetamines and cocaine, and is a member of the sodium:neurotransmitter symporter family. A repeat length polymorphism in the promoter of this gene has been shown to affect the rate of serotonin uptake and may play a role in sudden infant death syndrome, aggressive behavior in Alzheimer disease patients, and depression-susceptibility in people experiencing emotional trauma.

抗原: Synthetic peptide of human SLC6A4

经过测试的应用: ELISA, IHC

推荐稀释比: IHC: 50-200; ELISA: 2000-5000

种属反应性: Rabbit

克隆性: Rabbit Polyclonal

亚型: Immunogen-specific rabbit IgG


纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg²⁺ and Ca²⁺), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Metabolism, Neuroscience


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 220361(SLC6A4 Antibody) at a dilution of 1/50(Cytoplasm).



In comparison with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the synthetic peptide and then with 220361(Anti-SLC6A4 Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using 220361(Anti-SLC6A4 Antibody) at a dilution of 1/50.



In comparison with the IHC on the left, the same paraffin-embedded Human thyroid cancer tissue is first treated with synthetic peptide and then with D261429(Anti-SLC6A4 Antibody) at dilution 1/50.



Product Description

Pioneering GTPase and Oncogene Product Development since 2010
